Lupin secures USFDA approval for Dapagliflozin tablets

08 Apr 2026 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg. The USFDA has approved Lupin’s Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labeling.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2300.65 7.10 (0.31%)
09-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.00
Dr. Reddys Lab 1209.20
Cipla 1225.00
Zydus Lifesciences 903.35
Lupin 2300.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×